Journal
EXPERT REVIEW OF VACCINES
Volume 16, Issue 12, Pages 1181-1190Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2017.1393335
Keywords
Streptococcus pneumoniae; pneumococcal conjugate vaccines; pneumococcal whole-cell vaccine; pneumococcal protein vaccines; nasopharyngeal colonization; clinical trial; pathogenesis
Categories
Funding
- National Institute of Health [NIH R01 08671]
Ask authors/readers for more resources
Introduction: Epidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to be continued reformulations because there are many new emerging serotypes expressed by pneumococci.Areas covered: Mechanisms of protection by next-generation whole-cell vaccine (WCV) and/or multi-component pneumococcal purified protein vaccines (PPVs) in development for prevention of pneumococcal infections.Expert commentary: A long-term strategy for prevention of pneumococcal disease will likely include WCV and PPVs. However these vaccines will impact disease pathogenesis in a different manner than PCVs. Prevention of pneumococcal NP colonization should not be expected, nor is it desirable because risks for NP colonization by other replacement organisms into the ecological niche vacated by all pneumococci may have consequences. The expression biology of capsule and surface protein antigens are phase dependent. Therefore, the immune response will be different and the mechanism of protection divergent. WCVs and PPVs may be alternative strategies in low income developing countries to protect against invasive disease and reduce NP carriage load.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available